HOME >> BIOLOGY >> NEWS
Leibniz Prize winners 2003

cal Cytobiology and Cytopathology at the Philipps University in Marburg.

Prof. Dr. Christof Niehrs (40), development biology/genetics/zoology, German Cancer Research Centre in Heidelberg (1.55 million euros)

Christof Niehrs is well-known around the world as the development biologist who has answered many of the central questions in his field. His answers, together with an understanding of the underlying genomes, have laid the foundations for future contributions to questions which have not yet been answered, such as the question of shape and size in biology. Christof Niehrs has made his name in three fields of research:

    For studying mesoderm formation in amphibians (xenopus) he developed a gene expression screen for analysing gene activity in xenopus embryos. In the course of this research a number of control genes were identified which play a part in the development of the embryo.

    A second key focus of Niehrs' work relates to the Spemann organiser function, a piece of tissue from the amphibian embryo which has the power to induce a complete new embryo following transplantation.

    Possibly the most spectacular work presented by Christof Niehrs has been on the development mechanism of the embryo's head; this work has helped to solve one of the central problems which hampered even Spemann's research results.

Christof Niehrs studied biochemistry at the Free University of Berlin. After obtaining his doctorate there he moved to a postdoctoral post at the University of California in Los Angeles. In the years following 1994 he developed his own study group at the German Cancer Research Centre in Heidelberg. Following his qualification as a university professor in 1997, at the age of 36 he was offered a C4 professorship in biochemistry at the University of Bochum. Since then he has been offered professorships at the University of Karlsruhe and at the German Cancer Research Centre in Heidelberg.

Prof. Dr. Fer
'"/>

Contact: Ursula Rogmans-Beucher
ursula.rogmans-beucher@dfg.de
49-228-885-2726
Deutsche Forschungsgemeinschaft
3-Apr-2003


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. Leibniz Prizewinners 2004
2. Prizes awarded in the 2002 Gottfried Wilhelm Leibniz Programme
3. Leibniz Prize Winners 1999 - Most Highly Endowed German Promotional Prize For Ten Scientists
4. Half-million dollar landmark achieved for the Methuselah Mouse Prize
5. Winner of 2004 EMBO Science Writing Prize announced
6. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
7. Stuart Lipton honored with Jung Prize for Medicine
8. 2004 Max Planck Research Prize for Martin Vingron and Eugene W. Myers
9. Scripps research scientist wins 2004 Koch Prize
10. Ohio State wetlands professor wins prestigious Water Prize
11. Tony Hunter and Raymond N. DuBois awarded Landon-AACR Prizes for Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Leibniz Prize winners

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: